Chronic pain and gait analysis in dogs with degenerative hip joint disease treated with repeated intra-articular injections of platelet-rich plasma or allogeneic adipose-derived stem cells

Okamoto-Okubo, Celina Emiko; Cassu, Renata Navarro; Joaquim, Jean Guilherme Fernandes; Mesquita, Luciane dos Reis; Rahal, Sheila Canevese; Oliveira, Hugo Salvador; Takahira, Regina Kiomi; Arruda, Isadora; Maia, Leandro; Landim, Fernanda da Cruz; Luna, Stélio Pacca Loureiro

doi:10.1292/jvms.20-0730

Cited by 16 publications

(15 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One recent study (Okamoto‐Okubo et al . 2021) reported HCPI correlated well with objective gait analysis when assessing response to treatment. Recently, the HCPI has been used to identify previously undiagnosed OA cases and assess the response to carprofen treatment by monitoring pain and functional mobility (Wright et al .…”

Section: Subjective Measurements Of Canine Mobility Assessmentmentioning

confidence: 87%

“…The HCPI has been frequently used to assess the therapeutic response to treatment for OA (Hielm-Björkman et al 2009a, 2009b, Hielm-Björkman et al 2012. One recent study (Okamoto-Okubo et al 2021) reported HCPI correlated well with objective gait analysis when assessing response to treatment. Recently, the HCPI has been used to identify previously undiagnosed OA cases and assess the response to carprofen treatment by monitoring pain and functional mobility (Wright et al 2022), providing further rationale for the use of CMIs in clinical practice to assess early onset mobility impairments associated with MSD, or for longitudinal monitoring of OA.…”

Section: Clinical Metrology Instrumentsmentioning

confidence: 99%

See 1 more Smart Citation

An update on mobility assessment of dogs with musculoskeletal disease

Clark

Comerford

2023

J of Small Animal Practice

View full text Add to dashboard Cite

Mobility impairments associated with musculoskeletal diseases, such as osteoarthritis and degenerative joint disease, affect approximately 200,000 dogs annually and pose a notable challenge to canine health and welfare. Osteoarthritis causes the remodelling of synovial joints, alongside inflammation and impaired mechanical function which can be extremely debilitating. Secondary osteoarthritis commonly affects dogs and can be exacerbated by previous joint abnormalities, such as patellar luxation or cranial cruciate ligament rupture. Although musculoskeletal diseases can affect dogs of any age, the early subtle signs of gait abnormalities are perhaps missed by owners, thus, dogs may be in the latter stages of osteoarthritis progression when they are presented to veterinarians. Dogs showing subtle signs of gait abnormalities must be presented to veterinary practices for acute diagnosis to prevent long‐term deterioration. Musculoskeletal diseases, such as osteoarthritis and degenerative joint disease, are commonly diagnosed via visible radiographic changes. However, veterinarians can use a combination of subjective and objective clinical scoring systems, such as clinical metrology instruments and gait assessment in conjunction with radiography to aid their diagnosis and longitudinal monitoring of musculoskeletal diseases. These scoring systems may be more sensitive to earlier signs of mobility impairments in dogs, ultimately, promoting increased canine health and welfare by enabling pain reduction, improvement of muscle strength and preservation of joint function. Current canine mobility scoring systems available to veterinarians will be discussed in turn throughout this review for implementation into clinical practice.

show abstract

Section: Subjective Measurements Of Canine Mobility Assessmentmentioning

confidence: 87%

Section: Clinical Metrology Instrumentsmentioning

confidence: 99%

An update on mobility assessment of dogs with musculoskeletal disease

Clark

Comerford

2023

J of Small Animal Practice

View full text Add to dashboard Cite

show abstract

“…Both HA and PRP improve joint pain and mobility in people. Evidence is still limited in veterinary medicine but seems to indicate positive effects on pain and function when intra-articular HA or PRP are used alone or in combination with MSC in dogs with OA (Nganvongpanit et al 2013, Carapeba et al 2016, Venator et al 2020, Brondeel et al 2021, Okamoto-Okubo et al 2021.…”

Section: Therapies Administered By Intra-articular Injectionsmentioning

confidence: 99%

2022 WSAVA guidelines for the recognition, assessment and treatment of pain

Monteiro

Lascelles

Murrell

et al. 2022

J of Small Animal Practice

View full text Add to dashboard Cite

Animal sentience refers to the capacity of animals to feel both positive and negative emotions including that of pain. As veterinary health professionals, we have a medical and ethical duty to mitigate suffering from pain to the best of our ability. In 2014, the first Global Pain Council World Small Animal Veterinary Association (WSAVA) Guidelines for the Recognition, Assessment and Treatment of Pain was published and remains to this day one of the most relevant and widespread documents of its kind. The 2022 WSAVA Global Pain Management Guidelines evolves from the first document with updated scientific information reflecting major advances in veterinary pain medicine in the last decade. This document is designed to provide the user with easy-to-implement, core fundamentals on the successful recognition and treatment of pain in the day-to-day small animal clinical practice setting. It provides basic and practical information with an extensive reference list to guide those who want to further their knowledge on pain management. The 2022 WSAVA Global Pain Management Guidelines should be easily implemented regardless of practice setting and/or location for the promotion and advance of pain management and animal welfare. FIG 4. Peripheral sensitisation results in increased sensitivity around the lesion site. Affected patients may exhibit signs of hyperalgesia and allodynia. Adapted from Monteiro & Simon (2022). PGs Prostaglandins, NGF Nerve growth factor FIG 5. The constant noxious input (electrical signal) from the periphery to the spinal cord results in central sensitisation. Central sensitisation is the result from increased pain facilitation and decreased pain inhibition. Neuroplasticity and neuroimmune interactions also contribute to this phenomenon

show abstract

“…In addition, a combination of ADSCs with PRP in a rat model has shown that PRP potentiates the effect of ADSCs in damaged articular cartilage [ 33 ]. Recently, Okamoto-Okubo et al reported the best results with allogenic ADSCs over PRP in dogs with bilateral degenerative hip joint disease [ 80 ].…”

Section: Bioregenerative Therapies In Osteoarthritismentioning

confidence: 99%

Cell and Cell Free Therapies in Osteoarthritis

et al. 2021

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common articular disease in adults and has a current prevalence of 12% in the population over 65 years old. This chronic disease causes damage to articular cartilage and synovial joints, causing pain and leading to a negative impact on patients’ function, decreasing quality of life. There are many limitations regarding OA conventional therapies—pharmacological therapy can cause gastrointestinal, renal, and cardiac adverse effects, and some of them could even be a threat to life. On the other hand, surgical options, such as microfracture, have been used for the last 20 years, but hyaline cartilage has a limited regeneration capacity. In recent years, the interest in new therapies, such as cell-based and cell-free therapies, has been considerably increasing. The purpose of this review is to describe and compare bioregenerative therapies’ efficacy for OA, with particular emphasis on the use of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP). In OA, these therapies might be an alternative and less invasive treatment than surgery, and a more effective option than conventional therapies.

show abstract

Chronic pain and gait analysis in dogs with degenerative hip joint disease treated with repeated intra-articular injections of platelet-rich plasma or allogeneic adipose-derived stem cells

Cited by 16 publications

References 42 publications

An update on mobility assessment of dogs with musculoskeletal disease

An update on mobility assessment of dogs with musculoskeletal disease

2022 WSAVA guidelines for the recognition, assessment and treatment of pain

Cell and Cell Free Therapies in Osteoarthritis

Contact Info

Product

Resources

About